No Data
SBTi Verifies GenScript Biotech Corp's Carbon Emission Reduction Goals, Marking a Major Sustainability Milestone!
[Brokerage Focus] BOCOM INTL maintains a Buy rating on Genscript Biotech (01548), driven by fundamental recovery and improved investment sentiment for valuation restoration.
Jingwu Financial News | BOCOM INTL released a Research Report stating that GENSCRIPT BIO (01548) is expected to see significant growth in Net income in 2024 compared to 2023, mainly due to: 1) One-time unrealized gains from the sale of Legend Biotech (LEGNUS/Buy) approximately 3.2 billion dollars, exceeding the company's previous estimate of 2-3 billion dollars; 2) Non-cash losses of 0.124 billion dollars related to the fair value changes of the preferred shares of Pengbo Bio, mainly from the contributions of the Li Xin transaction and macroeconomic improvement. After excluding the impact of the above two items, the company's adjusted Net income from non-cellular Business in 2024 compared to 2023.
Hong Kong Stock Early Report｜The three major US stock indices are closed for the holiday. TCL ELECTRONICS expects Net income to increase by over 60% year-on-year.
① Eight departments issued the "Action Plan for High-Quality Development of the New Energy Storage Manufacturing Industry." ② Sales of RBOB Gasoline Passenger Vehicles in the first month of this year dropped by over 20% compared to the previous month. ③ The Bank of Japan is likely to raise interest rates as early as May. ④ Baidu's gray testing for DeepSeek was launched today.
Genscript Biotech Divestment Gains Among Factors Supporting Results
GENSCRIPT BIO (01548.HK) profit alert: an anticipated significant increase in annual Net income compared to the same period last year.
Gelonghui reported on February 16 that GENSCRIPT BIO (01548.HK) announced that the group expects to achieve significant growth in Net income for the fiscal year ending December 31, 2024, compared to the fiscal year ending December 31, 2023. The expected increase in Net income is primarily attributed to the following reasons: (1) a one-time unrealized gain of approximately 3.2 billion USD from the sale of Legend Biotech. Legend Biotech Co., Ltd. ("Legend Biotech," whose shares are listed as American Depositary Shares on the Nasdaq Global Select Market in the USA) will be deconsolidated from the group effective October 18, 2024, and it will be reintroduced from that point on.
GENSCRIPT BIO: INSIDE INFORLATION: POSITIVE PROFIT ALERT
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
